{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:17:06Z","timestamp":1791166626989,"version":"4.1.0"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[1990,9,1]],"date-time":"1990-09-01T00:00:00Z","timestamp":652147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1990,9]]},"abstract":"<jats:p>A new type of norfloxacin-resistant mutant of Pseudomonas aeruginosa PAO was isolated. This mutant showed cross resistance to imipenem and chloramphenicol and hypersusceptibility to beta-lactam and aminoglycoside antibiotics. The new norfloxacin resistance gene nfxC was mapped near catA (46 min) on the PAO chromosome. Norfloxacin accumulation was decreased in the nfxC mutant; furthermore, the rate of imipenem diffusion through the outer membrane of the nfxC mutant was lower than that of the parent strain. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of outer membrane proteins showed a decrease of a 46-kilodalton protein and an increase of a 50-kilodalton protein in the nfxC mutant. We conclude the nfxC is a new norfloxacin resistance gene that affects outer membrane permeability to quinolones and other antimicrobial agents.<\/jats:p>","DOI":"10.1128\/aac.34.9.1757","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:05:50Z","timestamp":1340841950000},"page":"1757-1761","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":120,"title":["New norfloxacin resistance gene in Pseudomonas aeruginosa PAO"],"prefix":"10.1128","volume":"34","author":[{"given":"H","family":"Fukuda","sequence":"first","affiliation":[{"name":"Central Research Laboratories, Kyorin Pharmaceutical Co. Ltd., Tochigi-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hosaka","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Kyorin Pharmaceutical Co. Ltd., Tochigi-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Hirai","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Kyorin Pharmaceutical Co. Ltd., Tochigi-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Iyobe","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Kyorin Pharmaceutical Co. Ltd., Tochigi-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.34.9.1757","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.34.9.1757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:18:43Z","timestamp":1645456723000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.34.9.1757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,9]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1990,9]]}},"alternative-id":["10.1128\/AAC.34.9.1757"],"URL":"https:\/\/doi.org\/10.1128\/aac.34.9.1757","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,9]]},"assertion":[{"value":"1990-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}